Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure is a phase 3 interventional study registered as NCT06935409, led by Hansoh BioMedical R&D, and active but no longer recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of HS-20093 for Injection Versus Gemcitabine in Combination With Docetaxel in the Treatment of Osteosarcoma After Previous Second-line Treatment Failure (ARTEMIS-011). Planned enrolment is 117 participants (estimated). The study started in 2025-04-25 and primary completion is expected in 2026-08-31. No results have been posted on ClinicalTrials.gov.